161 related articles for article (PubMed ID: 36911986)
21. BAP1 loss defines a new class of renal cell carcinoma.
Peña-Llopis S; Vega-Rubín-de-Celis S; Liao A; Leng N; Pavía-Jiménez A; Wang S; Yamasaki T; Zhrebker L; Sivanand S; Spence P; Kinch L; Hambuch T; Jain S; Lotan Y; Margulis V; Sagalowsky AI; Summerour PB; Kabbani W; Wong SW; Grishin N; Laurent M; Xie XJ; Haudenschild CD; Ross MT; Bentley DR; Kapur P; Brugarolas J
Nat Genet; 2012 Jun; 44(7):751-9. PubMed ID: 22683710
[TBL] [Abstract][Full Text] [Related]
22. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
23. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract][Full Text] [Related]
25. The expanding role of BAP1 in clear cell renal cell carcinoma.
Kapur P; Rajaram S; Brugarolas J
Hum Pathol; 2023 Mar; 133():22-31. PubMed ID: 35932824
[TBL] [Abstract][Full Text] [Related]
26. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
27. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
Poehlman WL; Hsieh JJ; Feltus FA
Sci Rep; 2019 Feb; 9(1):2899. PubMed ID: 30814637
[TBL] [Abstract][Full Text] [Related]
28. Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
Ricketts CJ; Linehan WM
PLoS One; 2015; 10(10):e0140257. PubMed ID: 26484545
[TBL] [Abstract][Full Text] [Related]
29. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract][Full Text] [Related]
30. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
31. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
[TBL] [Abstract][Full Text] [Related]
32. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
33. Modeling Renal Cell Carcinoma in Mice:
Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
[TBL] [Abstract][Full Text] [Related]
34. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
35. Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing.
Lin PH; Huang CY; Yu KJ; Kan HC; Liu CY; Chuang CK; Lu YC; Chang YH; Shao IH; Pang ST
Oncol Lett; 2021 Feb; 21(2):169. PubMed ID: 33456545
[TBL] [Abstract][Full Text] [Related]
36. Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population.
Suh J; Jeong CW; Choi S; Ku JH; Kim HH; Kim K; Kwak C
BMC Urol; 2020 Aug; 20(1):125. PubMed ID: 32811483
[TBL] [Abstract][Full Text] [Related]
37. Genomics and clinical correlates of renal cell carcinoma.
Mitchell TJ; Rossi SH; Klatte T; Stewart GD
World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
[TBL] [Abstract][Full Text] [Related]
38. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.
Randall JM; Millard F; Kurzrock R
Cancer Metastasis Rev; 2014 Dec; 33(4):1109-24. PubMed ID: 25365943
[TBL] [Abstract][Full Text] [Related]
39. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
Walton J; Lawson K; Prinos P; Finelli A; Arrowsmith C; Ailles L
Nat Rev Urol; 2023 Feb; 20(2):96-115. PubMed ID: 36253570
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
